• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[F]FDG与前列腺特异性膜抗原（PSMA）配体双示踪剂PET/CT在前列腺癌中的诊断价值：一项更新的系统评价

Diagnostic value of dual-tracer PET/CT with [F]FDG and PSMA ligands in prostate cancer: an updated systematic review.

作者信息

Iacovitti Cesare Michele, Cuzzocrea Marco, Rizzo Alessio, Bauckneht Matteo, Delgado Bolton Roberto C, Paone Gaetano, Treglia Giorgio

机构信息

Division of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona and Lugano, Switzerland.

Division of Nuclear Medicine, Candiolo Cancer Institute, Turin, Italy.

出版信息

Front Med (Lausanne). 2025 Jul 9;12:1607227. doi: 10.3389/fmed.2025.1607227. eCollection 2025.

DOI:10.3389/fmed.2025.1607227
PMID:40703299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12283616/
Abstract

BACKGROUND

Prostate-specific membrane antigen (PSMA) ligand PET/CT has significantly improved prostate cancer (PCa) imaging. However, in patients with poorly differentiated PCa or neuroendocrine transdifferentiation, [F]fluorodeoxyglucose ([F]FDG) PET/CT may provide additional diagnostic information. This systematic review evaluates the diagnostic value of combining [F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.

METHODS

A systematic literature search of studies assessing the added diagnostic value of dual-tracer [F]FDG and PSMA ligands PET/CT in PCa patients was conducted using PubMed/MEDLINE and Cochrane Library databases and available information was summarized.

RESULTS

Fourteen studies ( = 901 patients) met the inclusion criteria. The dual-tracer approach identified [F]FDG-positive/PSMA-negative (FDG+/PSMA-) lesions in a subset of patients, particularly those with Gleason Score (GS) ≥ 9. However, in patients with GS < 8, [F]FDG PET/CT did not significantly improve lesion detection over PSMA ligand PET/CT alone.The presence of FDG+/PSMA- lesions correlated with aggressive tumor biology, increased risk of metastases, and worse prognosis.

CONCLUSION

Literature data showed that [F]FDG PET/CT may serve as a valuable complementary imaging modality for high risk PCa patients potentially influencing staging and treatment decisions. Future prospective studies are warranted to further elucidate the prognostic significance and cost-effectiveness of combining [F]FDG PET/CT with PSMA ligand PET/CT in PCa patients.

摘要

背景

前列腺特异性膜抗原（PSMA）配体PET/CT显著改善了前列腺癌（PCa）的成像。然而，在低分化PCa或神经内分泌转分化患者中，[F]氟脱氧葡萄糖（[F]FDG）PET/CT可能提供额外的诊断信息。本系统评价评估了[F]FDG PET/CT与PSMA配体PET/CT联合在PCa患者中的诊断价值。

方法

使用PubMed/MEDLINE和Cochrane图书馆数据库对评估双示踪剂[F]FDG和PSMA配体PET/CT在PCa患者中额外诊断价值的研究进行系统文献检索，并总结可用信息。

结果

14项研究（n = 901例患者）符合纳入标准。双示踪剂方法在一部分患者中发现了[F]FDG阳性/PSMA阴性（FDG+/PSMA-）病变，特别是那些Gleason评分（GS）≥9的患者。然而，在GS < 8的患者中，[F]FDG PET/CT与单独使用PSMA配体PET/CT相比，并未显著提高病变检测率。FDG+/PSMA-病变的存在与侵袭性肿瘤生物学、转移风险增加和预后较差相关。

结论

文献数据表明，[F]FDG PET/CT可能是高危PCa患者有价值的补充成像方式，可能影响分期和治疗决策。未来有必要进行前瞻性研究，以进一步阐明[F]FDG PET/CT与PSMA配体PET/CT联合在PCa患者中的预后意义和成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f088/12283616/202bb2b461ad/fmed-12-1607227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f088/12283616/202bb2b461ad/fmed-12-1607227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f088/12283616/202bb2b461ad/fmed-12-1607227-g001.jpg

相似文献

1
Diagnostic value of dual-tracer PET/CT with [F]FDG and PSMA ligands in prostate cancer: an updated systematic review.[F]FDG与前列腺特异性膜抗原（PSMA）配体双示踪剂PET/CT在前列腺癌中的诊断价值：一项更新的系统评价
Front Med (Lausanne). 2025 Jul 9;12:1607227. doi: 10.3389/fmed.2025.1607227. eCollection 2025.
2
123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.用于诊断神经母细胞瘤的123I-间碘苄胍闪烁扫描术和18F-氟代脱氧葡萄糖正电子发射断层显像
Cochrane Database Syst Rev. 2015 Sep 29;2015(9):CD009263. doi: 10.1002/14651858.CD009263.pub2.
3
Diagnostic Value of F-FDG and F-PSMA-1007 PET/CT in Bone Metastases from Prostate Cancer: Retrospective Comparative Analysis.¹⁸F-FDG和¹⁸F-PSMA-1007 PET/CT对前列腺癌骨转移的诊断价值：回顾性对比分析
Arch Esp Urol. 2025 Jun;78(5):572-578. doi: 10.56434/j.arch.esp.urol.20257805.77.
4
The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG-PET/CT）在结直肠癌术前分期中的价值：系统评价和经济评估。
Health Technol Assess. 2011 Sep;15(35):1-192, iii-iv. doi: 10.3310/hta15350.
5
[18F]FDG and [68Ga]Ga-PSMA dual-tracer total-body PET/CT and PET/MR in patients with prostate cancer.[18F]氟代脱氧葡萄糖和[68Ga]镓-前列腺特异性膜抗原双示踪剂全身正电子发射断层显像/计算机断层扫描及正电子发射断层显像/磁共振成像在前列腺癌患者中的应用
Q J Nucl Med Mol Imaging. 2025 Jun;69(2):146-156. doi: 10.23736/S1824-4785.25.03637-4.
6
68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.68Ga-PSMA-11 PET/CT 成像在脑胶质瘤中的应用及其与临床病理预后参数的相关性。
Clin Nucl Med. 2023 Dec 1;48(12):e559-e563. doi: 10.1097/RLU.0000000000004903. Epub 2023 Oct 23.
7
Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.氟-18-氟代脱氧葡萄糖（FDG）正电子发射断层扫描（PET）计算机断层扫描（CT）用于检测横纹肌肉瘤中的骨、肺和淋巴结转移。
Cochrane Database Syst Rev. 2021 Nov 9;11(11):CD012325. doi: 10.1002/14651858.CD012325.pub2.
8
A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.前列腺特异性膜抗原正电子发射断层扫描在前列腺癌明确治疗前诊断和初始分期中作用的综合系统评价与荟萃分析
Eur Urol. 2025 Jun;87(6):654-671. doi: 10.1016/j.eururo.2025.03.003. Epub 2025 Mar 27.
9
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.阴性前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描能否避免新诊断前列腺癌患者进行盆腔淋巴结清扫？一项以病理组织学为参考标准的系统评价和Meta分析
Eur Urol Oncol. 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17.
10
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.前列腺特异性膜抗原正电子发射断层扫描在评估根治性治疗后前列腺癌生化复发患者局部复发和远处转移中的作用：一项系统评价和荟萃分析。
Eur Urol. 2025 May 19. doi: 10.1016/j.eururo.2025.05.006.

本文引用的文献

1
Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during Lu/Ac treatment in neuroendocrine tumors and metastatic prostate cancer.靶向放射性配体疗法：神经内分泌肿瘤和转移性前列腺癌中镥/锕治疗期间的物理与生物学、内照射剂量学及其他实际问题
Theranostics. 2025 Mar 18;15(10):4368-4397. doi: 10.7150/thno.107963. eCollection 2025.
2
Prognostic value of [F]FDG- and PSMA-PET in patients evaluated for [Lu]Lu-PSMA therapy of mCRPC.[F]FDG和PSMA-PET在接受[Lu]Lu-PSMA治疗评估的mCRPC患者中的预后价值。
Eur J Nucl Med Mol Imaging. 2025 Mar 21. doi: 10.1007/s00259-025-07198-y.
3
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study.
三探针 PET 成像在 mCRPC 患者中确定的瘤内转移灶异质性及其与生存的相关性：3TMPO 队列研究。
J Nucl Med. 2024 Nov 1;65(11):1710-1717. doi: 10.2967/jnumed.124.268020.
4
Sequential [Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study.LuLu-PSMA-617 序贯治疗与多西他赛治疗转移性去势敏感性前列腺癌患者的疗效比较（UpFrontPSMA）：一项多中心、开放标签、随机、Ⅱ期临床研究。
Lancet Oncol. 2024 Oct;25(10):1267-1276. doi: 10.1016/S1470-2045(24)00440-6. Epub 2024 Sep 15.
5
Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [Ga]Ga-/[F]F-PSMA-11/-1007, [Ga]Ga-FAPI-46 and 2-[F]FDG PET/CT: a pilot study.在[Ga]Ga-/[F]F-PSMA-11/-1007、[Ga]Ga-FAPI-46 和 2-[F]FDG PET/CT 上检测晚期转移性去势抵抗性前列腺癌患者的肿瘤异质性：一项初步研究。
Eur J Nucl Med Mol Imaging. 2024 Dec;52(1):342-353. doi: 10.1007/s00259-024-06891-8. Epub 2024 Aug 29.
6
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancer.瘤内反应异质性与转移性去势抵抗性前列腺癌阿比特龙治疗的预后相关。
Med. 2024 Dec 13;5(12):1475-1484.e3. doi: 10.1016/j.medj.2024.07.020. Epub 2024 Aug 15.
7
The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.与 PSMA 靶向示踪剂相关的非特异性骨摄取的类人畸形：基于系统评价的定义。
Eur J Nucl Med Mol Imaging. 2024 Oct;51(12):3753-3764. doi: 10.1007/s00259-024-06797-5. Epub 2024 Jun 17.
8
[Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.[Lu]Lu-PSMA-617联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌患者（ENZA-p）：一项开放标签、多中心、随机、2期试验。
Lancet Oncol. 2024 May;25(5):563-571. doi: 10.1016/S1470-2045(24)00135-9. Epub 2024 Apr 12.
9
F-FDG PET Is Not Inferior to Ga-PSMA PET for Detecting Biochemical Recurrent Prostate Cancer with a High Gleason Score: A Head-to-Head Comparison Study.对于检测高 Gleason 评分的生化复发性前列腺癌，F-FDG PET 并不逊色于 Ga-PSMA PET：一项直接对比研究。
Diagnostics (Basel). 2023 Dec 19;14(1):7. doi: 10.3390/diagnostics14010007.
10
Combination of [F]FDG and [F]PSMA-1007 PET/CT predicts tumour aggressiveness at staging and biochemical failure postoperatively in patients with prostate cancer.正电子发射断层扫描/计算机断层扫描（PET/CT）融合 [F]FDG 和 [F]PSMA-1007 可预测前列腺癌患者分期时肿瘤侵袭性和术后生化失败。
Eur J Nucl Med Mol Imaging. 2024 May;51(6):1763-1772. doi: 10.1007/s00259-023-06585-7. Epub 2024 Jan 11.